

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED  
Representative: Joji Nakayama, Representative Director, President and CEO  
(Code no.: 4568, First Section, Tokyo Stock Exchange)  
Please address inquiries to Noriaki Ishida, Corporate Officer,  
Vice President, Corporate Communications Department  
Telephone: +81-3-6225-1126  
<http://www.daiichisankyo.com>

### **Daiichi Sankyo Launches New Generic Drugs Through its Daiichi Sankyo Espha Subsidiary**

Tokyo, Japan (December 12, 2014) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that its generics subsidiary, Daiichi Sankyo Espha, today launched nine new generic drugs with three new active ingredients.

#### Overview

##### 1. Product names/therapeutic categories

Product name	Therapeutic category	Original brand name
Levofloxacin Tablets 250mg "DSEP"	Broad-spectrum oral antibacterial agent	Cravit® Tablets 250mg, 500mg, Granules 10%
Levofloxacin Tablets 500mg "DSEP"		
Levofloxacin Granules 10% "DSEP"		
Candesartan Tablets 2mg "DSEP"	Persistent angiotensin II receptor antagonist	Blopress® Tablets 2,4,8,12
Candesartan Tablets 4mg "DSEP"		
Candesartan Tablets 8mg "DSEP"		
Candesartan Tablets 12mg "DSEP"		
Oxaliplatin I.V. Infusion Solution 50mg "DSEP"	Anti-malignant tumor agent	Elplat® I.V. Infusion Solution 50mg, 100mg
Oxaliplatin I.V. Infusion Solution 100mg "DSEP"		

##### 2. Product attributes

Daiichi Sankyo Espha's Levofloxacin Tablets 250mg, 500mg and Granules 10% "DSEP" (hereafter, Levofloxacin formulation) are an authorized generic drug manufactured from the same substance and additives and using the same manufacturing methods as the broad-spectrum oral antibacterial agent Cravit® Tablets 250mg, 500mg and Granules 10% (generic name: levofloxacin hydrate; hereafter, Cravit).

Daiichi Sankyo Espha will continue to collaborate with Daiichi Sankyo to meet the needs of patients and medical practitioners by promoting the appropriate usage of antibacterial drugs.

Meanwhile, regarding Cravit, Daiichi Sankyo will continue to provide information on efficacy and safety to medical practitioners based on accumulated usage results up to now.

Daiichi Sankyo Espha has continued to maintain a level of quality based on the quality management standards of the Daiichi Sankyo Group. Thanks to initiatives such as the world's first double-sided printing on tablets, Daiichi Sankyo Espha has contributed to increasing product added value through innovations in formulations and labeling to make drugs easier to ingest and harder for patients to mistakenly take. The company hopes to provide more appropriate generic drug options for patients and medical institutions in the future by further adding to the current authorized generic product lineup.

Images of DSEP tablets and PTP sheets

#### Levofloxacin Tablets 500mg "DSEP"



#### Candesartan Tablets 8mg "DSEP"



#### Oxaliplatin I.V. Infusion Solution 100mg "DSEP"



## **About Daiichi Sankyo Espha**

Daiichi Sankyo Espha was created in April 2010 to manufacture and market generic drugs and accommodate rising demand based on the spirit of Daiichi Sankyo Group corporate philosophy\* of supplying pharmaceuticals to address diverse medical needs. Daiichi Sankyo Espha strives to provide pharmaceuticals that provide peace of mind for users by fulfilling the most important pharmaceutical criteria of quality, information, and stable supply while delivering the economic benefits of generics.

## **Daiichi Sankyo Espha Company Overview**

Company name: Daiichi Sankyo Espha Co., Ltd.

Established: April 1, 2010

Business: manufacture and sale of pharmaceuticals

Capital: 450 million yen

Representative: President Hiroto Yoshikawa

Headquarters: 3-5-1, Nihonbashi, Honcho, Chuo-ku, Tokyo

\*Daiichi Sankyo Group corporate philosophy

To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs.